Compare
Cellectar Biosciences, Inc. vs Cingulate Inc. vs Synlogic, Inc. vs Aprea Therapeutics, Inc.
| Latest fiscal year | Cellectar Biosciences, Inc. CLRB | Cingulate Inc. CING | Synlogic, Inc. SYBX | Aprea Therapeutics, Inc. APRE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | n/a |
| Revenue growth (YoY) | n/a | n/a | -100.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$21.79M | -$22.45M | -$1.00M | -$12.60M |
| EPS (Diluted) | -$8.35 | -$4.44 | -$0.08 | -$1.93 |
| Operating cash flow | -$23.12M | -$17.25M | -$4.36M | -$12.89M |
| Free cash flow | -$23.12M | -$17.41M | -$4.36M | n/a |
| Cash & equivalents | $13.20M | $10.95M | $14.67M | $14.60M |
| Total assets | $14.98M | $15.07M | $15.45M | $15.93M |
| Total liabilities | $5.06M | $12.56M | n/a | n/a |
| Shareholders' equity | $8.54M | $2.51M | $11.86M | $12.44M |
| Return on year-end equity | -255.2% | -894.8% | -8.5% | -101.3% |
| Shares outstanding | 4.24M | 7.25M | 11.70M | 8.19M |
Revenue, most recent five fiscal years
| Fiscal year | Cellectar Biosciences, Inc. | Cingulate Inc. | Synlogic, Inc. | Aprea Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $0 Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | n/a | $8.0K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $3.37M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $1.18M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $1.75M Ended 2021-12-31 | n/a |